Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium

Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved ...
NPR

The Pulse

Go on an adventure into unexpected corners of the health and science world each week with award-winning host Maiken Scott. The Pulse takes you behind the doors of operating rooms, into the lab with ...